



**HCV Core Antigen as an alternative test to
Quantitative HCV RNA for assessment of SVR in
Chronic HCV infected patients treated with Direct
Acting Antiviral agents**

Thesis

Submitted for partial fulfillment of master degree
in Internal Medicine

By

Basant Moatz Abdelrhieem

M.B.B.Ch, Ain Shams University

Supervised by

Prof. Dr. Sherif Monier Mohamed

Professor of Internal Medicine and Gastroenterology
Faculty of Medicine - Ain Shams University

Asst. Prof. Dr. Nevine Ibrahim Musa

Assistant Professor of Internal Medicine and Gastroenterology
Faculty of Medicine - Ain shams University

Dr. Ramy Samir Ghait

Lecturer of Internal Medicine and Gastroenterology
Faculty of Medicine - Ain shams University

Faculty of Medicine
Ain Shams University
2018

Acknowledgement

"Praise to Allah, who has guided us to this; and we would never have been guided if Allah had not guided us". First and foremost, I'd like to express gratitude to Almighty Allah, the most gracious, the most merciful for helping throughout this work.

I would like to express my sincere appreciation to **Prof. Dr. Sherif Monier Mohamed** for his patience, motivation, enthusiasm, and immense knowledge. I could not have imagined having a better advisor and mentor for my study.

I am also most grateful for the generosity, kindness and endless support of **Asst. Prof. Dr. Nevine Ibrahim Musa**. The door to her office was always open whenever I ran into a trouble spot or had a question about my research or writing.

I am thankful as well for **Dr. Ramy Samir Ghait** who consistently allowed this paper to be my own work, but steered me in the right direction whenever he thought I needed it.

Finally, I must express my very profound gratitude to my parents for providing me with unfailing support and continuous encouragement throughout my years of study and the process of researching and writing this thesis. This accomplishment would not have been possible without them. Thank you.

Basant Moatz Abdelrhieem

List of Contents

Title	Page
▪ List of Abbreviations	I
▪ List of Tables	VI
▪ List of Figures	XIII
▪ Introduction	1
▪ Aim of the Study	4
▪ Review of Literature	5
▪ Patients and Methods	67
▪ Results	80
▪ Discussion	138
▪ Conclusion	151
▪ Recommendations	152
▪ Summary	153
▪ References	155
▪ Arabic Summary	--

List of Abbreviations

$\bar{X}d$	Mean's difference between pre and post
$\bar{X}1$	Mean of the first group
$\bar{X}2$	Mean of the second group.
AFP	Serum Alpha-Fetoprotein
Ag/Ab	Antigen/Antibody
ALB	Albumin
ALT	Alanine Transaminase
ANOVA	Analysis of Variance
Apo	Apolipoprotein
APRI	Aminotransferase to Platelet Ratio Index
ARFI	Acoustic Radiation Force Impulse
AST	Aspartate Transaminase
AUROC	Area under the Receiver Operating Characteristic Curve
CBC	Complete Blood Count
CD	Cluster of Differentiation
CI	Confidence Interval
CIA	Chemiluminescence Immunoassay
CLDN1	Claudin-1
CLDs	Cytoplasmic Lipid Droplets
CLIA	Chemiluminescent Immunoassay
CT	Computed Tomography
CYP	Cytochrome
DAAs	Direct-Acting Antivirals
DAC	Daclatasvir
DGAT1	Diacylglycerol Acyltransferase-1

List of Abbreviations

DSV	Dasabuvir
EBR	Elbasvir
ECG	Electrocardiogram
EDHS	Egypt Demographic and Health Surveys
EGFR	Epidermal Growth Factor Receptor
eGFR	Estimated Glomerular Filtration Rate
EHIS	Egyptian Health Issue Survey
EIA	Enzyme Immunoassay
ELISA	Enzyme-Linked Immunosorbent Assay
ER	Endoplasmic Reticulum
FBS	Fasting blood sugar level
FDA	Food and Drug Administration
FIB4	Fibrosis-4
FU	Follow up
GLE	Glecaprevir
GT	Genotype
GZR	Grazoprevir
HAV	Hepatitis A Virus
Hb	Hemoglobin
HbA1c	Hemoglobin A1c
HBV	Hepatitis B Virus
HCC	Hepatocellular Carcinoma
HCV	Hepatitis C Virus
HIV	Human Immunodeficiency Virus
HRP	Horseradish Peroxidase
IFN	Interferon

List of Abbreviations

INR	International Normalized Ratio
IUs	International Units
kPa	Kilopascal
LDL	Low-Density Lipoproteins
LDV	Ledipasvir
LVPs	Lipoviroparticles
MELD	Model for End-Stage Liver Disease
MRI	Magnetic Resonance Imaging
NAAT	Nucleic Acid Amplification Test
NAT	Nucleic Acid Test
NCCVH	National Committee for Control of Viral Hepatitis
Nis	Nucleotide Inhibitors
NNIs	Non-nucleotide Inhibitors
NPV	Negative Predictive Value
NS	Non Structural
OBV	Ombitasvir;
OCLN	Occludin
OD	Optical Density
PAT	Parenteral Anti-schistosomiasis Treatment
PAUS	Pelvi-abdominal Ultrasound
PCR	Polymerase Chain Reaction
PegIFN	Pegylated Interferon
P-gp	P-glycoprotein
PIB	Pibrentasvir
PIs	Protease Inhibitors

List of Abbreviations

PLT	Platelets
PPV	Positive Predictive Value
PTV	Paritaprevir
PV	Portal Vein
PWIDs	People Who Inject Drugs
R	Ritonavir
RAS	Resistance Associated Substitutions
RBV	Ribavirin
RdRP	RNA-dependent RNA polymerase
RIBA	Recombinant Immunoblot Assay
RIG-1	Retinoic acid-Inducible gene 1
RNA	Ribonucleic acid
ROC	Receiver Operating Characteristic
RT-qPCR	Real-Time quantitative Polymerase Chain Reaction
SD	Standard Deviation
SE1	Standard error of the first group
SE2	Standard error of the second group
SEd	Standard error of the difference between pre and post
SOF	Sofosbuvir
SPSS	Statistical Package for the Social Sciences
SR-BI	Scavenger Receptor class B type I
SVR	Sustained Virologic Response
TBR	Total Bilirubin level
TLC	Total Leucocytic Count

List of Abbreviations

TMB	Tetramethylbenzidine
USA	United States of America
UTRs	Untranslated Regions
VEL	Velpatasvir
VLDL	Very-Low-Density Lipoproteins
VOX	Voxilaprevir
WHO	World Health Organization

List of Tables

Table No.	Title	Page
Table (1):	Non-invasive marker cut-offs for prediction of stages of fibrosis, including F3 (advanced fibrosis) and F4 (cirrhosis).....	40
Table (2):	HCV DAAs approved in Europe in 2018	46
Table (3):	IFN-free, ribavirin-free combination treatment regimens available for treatment naïve patients.....	47
Table (4):	Treatment recommendations for patients with chronic hepatitis C without cirrhosis, including treatment-naïve patients	48
Table (5):	Treatment recommendations for patients with chronic hepatitis C with compensated (Child-Pugh A)	49
Table (6):	Commonly used regimen of treatment for HCV by Egyptian national control program.....	66
Table (7):	Characteristics of studied subjects with regard to age	81
Table (8):	Characteristics of studied subjects with regard to gender	81
Table (9):	Characteristics of studied subjects with regard to prevalence of Diabetes Mellitus.....	82

List of Tables

Table No.	Title	Page
Table (10):	Characteristics of diabetic subjects with regard to HbA1c level.....	82
Table (11):	Characteristics of studied subjects with regard to baseline fibrosis score as assessed by fibroscan	83
Table (12):	Characteristics of studied subjects with regard to spleen and liver sizes and portal vein diameter, as assessed by PAUS before DAA treatment.....	84
Table (13):	Classification of studied subjects as easy to treat and difficult to treat	84
Table (14):	Characteristics of studied subjects with regard to the regimen of Direct Acting Antiviral treatment employed....	85
Table (15):	Characteristics of studied subjects with regard to achievement of sustained virologic response (SVR) after 12 weeks of DAAs treatment as defined by Quantitative RNA measured via PCR.....	86
Table (16):	Characteristics of studied subjects with regard to achievement of sustained virologic response (SVR) after 12 weeks of DAAs treatment as defined by HCV core antigen level.....	87

List of Tables

Table No.	Title	Page
Table (17):	Characteristics of studied subjects with regard to HCV RNA as quantified by PCR, pre-treatment and 12 weeks after the end of treatment to define SVR 12	87
Table (18):	Characteristics of studied subjects with regard to the level of HCV core antigen pre-treatment and 12 weeks after the end of treatment to define SVR 12.....	90
Table (19):	Characteristics of studied subjects with regard to Total Leucocyte Count ..	93
Table (20):	Characteristics of studied subjects with regard to Hemoglobin level.....	95
Table (21):	Characteristics of studied subjects with regard to Platelet (PLT) count	97
Table (22):	Characteristics of studied subjects with regard to INR.....	99
Table (23):	Characteristics of studied subjects with regard to AST	101
Table (24):	Characteristics of studied subjects with regard to ALT.....	103
Table (25):	Characteristics of studied subjects with regard to Total Bilirubin level (TBR).....	105

List of Tables

Table No.	Title	Page
Table (26):	Characteristics of studied subjects with regard to serum Albumin (ALB)....	107
Table (27):	Characteristics of studied subjects that had been treated with sofosbuvir and daclatasvir with regard to HCV RNA as quantified by PCR, pre-treatment and 12 weeks after the end of treatment to define SVR 12	109
Table (28):	Characteristics of studied subjects that had been treated with sofosbuvir and daclatasvir, with regard to the level of HCV core antigen pre-treatment and 12 weeks after the end of treatment to define SVR 12	112
Table (29):	Characteristics of studied subjects that had been treated with sofosbuvir and simeprevir with regard to HCV RNA as quantified by PCR, pre-treatment and 12 weeks after the end of treatment to define SVR 12	115
Table (30):	Characteristics of studied subjects that had been treated with sofosbuvir and simeprevir, with regard to the level of HCV core antigen pre-treatment and 12 weeks after the end of treatment to define SVR 12	118

List of Tables

Table No.	Title	Page
-----------	-------	------

Table (31):	Characteristics of studied subjects that had been treated with sofosbuvir and daclatasvir and ribavirin with regard to HCV RNA as quantified by PCR, pre-treatment and 12 weeks after the end of treatment to define SVR 12	121
Table (32):	Characteristics of studied subjects that had been treated with sofosbuvir, daclatasvir and ribavirin, with regard to the level of HCV core antigen pre-treatment and 12 weeks after the end of treatment to define SVR 12.....	124
Table (33):	Characteristics of studied subjects with regard to HCV RNA levels pre-treatment and 12 weeks after the end of treatment in male subjects as compared to female subjects	127
Table (34):	Characteristics of studied subjects with regard to HCV core antigen levels pre-treatment and 12 weeks after the end of treatment in male subjects as compared to female subjects	128
Table (35):	Correlation between baseline HCV RNA and HCV core antigen levels	129

List of Tables

Table No.	Title	Page
Table (36):	Correlation between HCV RNA and HCV core antigen levels 12 weeks after the end of treatment.....	130
Table (37):	Correlation between age and HCV RNA level (baseline and 12 weeks post-treatment) as well as age and HCV core antigen level (baseline and 12 weeks post-treatment)	131
Table (38):	Correlation between different laboratory and abdominal US parameters, before DAAs treatment, and baseline HCV core antigen levels.....	132
Table (39):	Correlation between different laboratory parameters and HCV core antigen levels 12 weeks after the end of treatment	133
Table (40):	Correlation between baseline fibrosis stage and baseline HCV core antigen levels.....	134
Table (41):	Correlation between baseline HCV core antigen levels and HCV RNA levels in studied subjects with regard to the DAAs regimen employed	135
Table (42):	Correlation between HCV core antigen levels and HCV RNA levels, 12 weeks post-treatment, in studied subjects with regard to the DAAs regimen employed	136

List of Tables

Table No.	Title	Page
Table (43):	Diagnostic performance of HCV core antigen in detecting chronic HCV infection.....	137